FNA

ANALYST NOTE: FNA (Paragon 28, Inc.) Date: 2026-06-13 Current Price: $13.09

1. Structural Readiness

State: Context-Only / Forming

Technical Configuration:

• Conservative Entry: Not yet defined (awaiting confirmed breakout).
• Aggressive/Pre-Breakout Entry: N/A (Current price action is within the consolidation range).
• Breakout Level: Not yet fired.
• Current Price: $13.09.
• Extension: Not applicable (price has not broken out).
• ATR Context: Current ATR is 0.4% (sub-threshold). This indicates low volatility and a lack of immediate momentum, consistent with a "forming" or consolidation phase rather than an active breakout.

Interpretation:

2. Thesis Layer

Thesis Classification: TACTICAL / Setup-Led Secular Exposure: None named at this date.

This is a tactical, setup-led name. There is no named macro or secular thesis driving the immediate conviction stack. The investment case must be judged strictly on the quality of the technical setup (the forming coil) and the underlying business fundamentals as recorded by management. No external thematic tailwinds (e.g., specific regulatory shifts or secular demographic booms) are explicitly cited in the evidence base for this specific date.

3. Business Overview

Company: Paragon 28, Inc. (FNA) Industry: Medical Devices (Foot & Ankle Surgical Systems) Business Model: Development, manufacturing, and global distribution of advanced surgical systems tailored for foot and ankle procedures. The company sells directly to hospitals and ambulatory surgery centers via a network of direct sales representatives and stocking distributors.

Key Fundamentals (as of 2026-06-13):

• Product Portfolio: The company offers a comprehensive suite of solutions including:
• Plating Systems: Gorilla series (Lisfranc, Lapidus, lateral column, calcaneus, NC fusions) and Silverback systems.
• Screw Systems: Monster, Mini Monster, and Joust beaming lines for bone reconstruction and fixation.
• Joint Replacement: APEX 3D total ankle replacement systems and talus spacers.
• Correction Systems: Phantom intramedullary nail systems for severe hallux valgus.
• Orthobiologics: Bone wedges, grafts, matrices, and synthetic materials.
• Operational Scale: As of the last reported quarter (Q3 2024), the company served 2,244 active surgeon customers (up 9% YoY) and maintained a U.S. sales rep roster of 284 (up 10.5% YoY).
• Financial Trajectory (Management Expectations):
• Revenue: Q3 2024 revenue was a record $62.3 million (18.1% reported growth). Management guided full-year 2024 net revenue to $252M–$256M (16.5%–18.3% growth).
• Profitability: Q3 2024 marked an inflection point with Adjusted EBITDA of $432,000 (first positive quarter since IPO in Oct 2021).
• Forward Guidance: Management communicated priorities to be Adjusted EBITDA positive in 2025 and Free Cash Flow (FCF) positive in 2026. As of the Q3 2024 transcript, management stated they were "ahead of schedule" to deliver on these priorities.

4. Archetype and Conviction

Archetype: Growth Leader Rationale: The company fits the "Growth Leader" archetype due to its double-digit revenue growth (18.1% in Q3 2024), expanding customer base, and successful execution of a turnaround strategy that moved the company from losses to profitability ahead of schedule. The product portfolio is deep and diversified across plating, screws, joint replacement, and orthobiologics, reducing reliance on a single SKU.

Valuation & Financial Spine:

• Consensus EPS: Forward consensus EPS for FY1 is -0.35 and FY2 is -0.24.
• Context: While the company reported positive Adjusted EBITDA in Q3 2024, the consensus EPS remains negative for the forward years. This suggests the market is pricing in a transition period where GAAP profitability (including stock-based comp, R&D, and D&A) has not yet fully caught up with Adjusted EBITDA, or that the "FCF positive in 2026" guidance is the critical inflection point for valuation rerating.
• Conviction Stack:
• *Thesis Strength:* Low (Tactical/Setup-led).
• *Evidence Quality:* High (Strong operational metrics, clear product roadmap, management execution on guidance).
• *Structural Quality:* Moderate (Forming coil, low volatility).
• *Setup Readiness:* Partial (Forming, awaiting breakout).
• *Rerating Potential:* Dependent on the realization of the 2026 FCF guidance and the transition from Adjusted EBITDA to GAAP profitability.

ATR Analysis: Current ATR is 0.4% (sub-threshold). In the StoryStocks canon, high volatility (4–6%) is the historical sweet spot for breakouts. A sub-threshold ATR indicates the stock is currently "quiet." This supports the "Forming" classification but suggests that a breakout will require a significant expansion in volatility to be confirmed.

5. Invalidation, Strengthening, and Gaps

Invalidation Triggers:

• Fundamental: A miss on the 2026 Free Cash Flow positive guidance or a reversal in the growth trajectory (e.g., revenue growth dropping below 10%).
• Operational: A significant reduction in the active surgeon customer base or sales rep productivity.

Strengthening Triggers:

• Technical: A high-volume breakout above the consolidation range (forming coil breakout) accompanied by an expansion in ATR.
• Fundamental: Confirmation of GAAP profitability ahead of the 2026 FCF target, or an upward revision of full-year guidance.
• Product: Successful launch of new products (e.g., APEX 3D or new orthobiologics) driving incremental revenue.

Evidence Gaps:

• Missing 2026 Data: The evidence base relies heavily on Q3 2024 transcripts and 2024 guidance. There is no specific 2025 or 2026 earnings data or actual results provided for the current date (2026-06-13), only the *expectations* recorded in 2024.
• Missing Volatility Context: While current ATR is 0.4%, the ATR at the time of a potential breakout is unknown.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Record Q3 2024 revenue of $62.3M with 18.1% growth; First positive Adjusted EBITDA since IPO; Management states they are ahead of schedule on 2025 EBITDA and 2026 FCF guidance; 9% increase in active surgeon customers. Key risks: Forward consensus EPS remains negative for FY1 and FY2; Current ATR is sub-threshold (0.4%) indicating low momentum; Technical setup is "forming" and not yet confirmed; Lack of specific 2026 actuals in the evidence base. Sizing hint: Position size should be conservative given the "forming" status and sub-threshold volatility; treat as a partial position pending breakout confirmation. Expected path: Management expectations for 2026 FCF positivity drive the narrative; if the company delivers on the 2026 target, the stock may re-rate from a growth story to a profitability story, potentially triggering a technical breakout. Expected horizon: 6 to 12 months (aligned with the realization of the 2026 FCF guidance and technical breakout confirmation).